Maryam Rahman
Associate Professor/M.D. | University of Florida
Gainesville, FL, UNITED STATES
Dr. Maryam Rahman specializes in brain tumor immunotherapy, advanced surgical management of gliomas, and skull base tumors.
Biography
Dr. Maryam Rahman is a neurosurgeon who specializes in the care of patients with benign and malignant brain tumors. She has expertise in awake mapping, the use of intraoperative MRI, and laser ablation for the treatment of brain tumors. She has a research focus on brain tumor immunotherapy and has developed novel personalized medicine approaches for the treatment of brain tumors.
Areas of Expertise (6)
LITT
Meningioma
Brain Tumors
Immunotherapy
Brain Met
Shcwannoma
Media Appearances (1)
PI: Dr. Rahman – Gators Against Gliomas: Translational Neuro-oncology Laboratory
UF Health tv
2024-01-01
Discovery of cures for patients with brain tumors through ethical scientific inquiry, collaboration, cutting-edge clinical care, education and mentorship. The laboratory focuses on identifying novel immunotherapy approaches to overcome resistance in patients with brain cancer. Current projects include development of vaccines for the treatment of brain tumors and combining immunotherapy with MRI guided laser ablation.
Articles (4)
Opiate Use Patterns Following Surgery for High Grade Glioma
World NeurosurgeryGrace Hey, et. al
2024-12-17
Opiate drugs are commonly prescribed for postoperative pain relief following craniotomy. The aim of this study was to assess opiate use in patients undergoing craniotomy for high-grade glioma and to identify risk factors contributing to prolonged opiate use.
Duration of Prophylactic Levetiracetam After Surgery for Brain Tumor: A Prospective Randomized Trial
NeurosurgeryMaryam Rahman, et. al
2023-01-01
Levetiracetam is commonly used as a prophylactic antiseizure medication in patients undergoing surgical resection of brain tumors. To quantitate side effects experienced in patients treated with 1 week vs 6 weeks of prophylactic levetiracetam using validated measures for neurotoxicity and depression.
Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma
The Journal of Clinical InvestigationDongjiang Chen, et al.
2022-04-15
Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging evidence suggests that TTFields may also induce inflammation. However, the mechanism underlying this property and whether it can be harnessed therapeutically are unclear.
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
The Journal for ImmunoTherapy of CancerFarhad Dastmalchi, et. al
2019-11-21
Dendritic cell (DC) vaccine efficacy is directly related to the efficiency of DC migration to the lymph node after delivery to the patient. We discovered that a naturally occurring metabolite, sarcosine, increases DC migration in human and murine cells resulting in significantly improved anti-tumor efficacy. We hypothesized that sarcosine induced cell migration was due to chemokine signaling.
Social